Literature DB >> 19766789

Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination.

Terumoto Koike1, Ken-ichi Togashi, Toru Shirato, Seijiro Sato, Hiroyuki Hirahara, Masaaki Sugawara, Fumiaki Oguma, Hiroyuki Usuda, Iwao Emura.   

Abstract

BACKGROUND: The establishment of limited resection procedures for non-small cell lung cancer is expected. Many groups have suggested noninvasive bronchioloalveolar carcinoma (BAC) to be a potential indication for limited resection.
METHODS: We designed a prospective phase II study evaluating limited resection for noninvasive BAC diagnosed by intraoperative pathologic examination. From 1999 to 2007, limited resection was the procedure in 46 patients (16 men and 30 women; median age, 69 years; range, 49 to 83) who were diagnosed intraoperatively as having noninvasive BAC. The first end point was the predictive value of the intraoperative pathologic examination for noninvasive BAC diagnosis. The second end point was overall survival, disease-free survival, and cancer-specific survival, calculated using the Kaplan-Meier method.
RESULTS: We performed wedge resections for 44 patients and segmentectomy for 2 patients. Permanent pathologic examination revealed 3 patients had primary lung adenocarcinomas other than noninvasive BAC. The predictive value of intraoperative pathologic examination for noninvasive BAC diagnosis was 94%. During a median 51-month follow-up, there were only 2 cancer unrelated deaths. The 5-year overall survival rate and the disease-free survival rate were 93%, and the 5-year cancer-specific survival rate was 100%.
CONCLUSIONS: The results of our prospective phase II study indicate that limited resection, mainly by wedge resection, is a potentially curative surgical procedure and may be an acceptable alternative to lobectomy for patients with noninvasive BAC. Furthermore, an intraoperative pathologic diagnosis of noninvasive BAC is strongly predictive and allows for an intraoperative decision to perform a limited resection in these patients.

Entities:  

Mesh:

Year:  2009        PMID: 19766789     DOI: 10.1016/j.athoracsur.2009.06.051

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  29 in total

Review 1.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Analysis of feasibility and safety of complete video-assisted thoracoscopic resection of anatomic pulmonary segments under non-intubated anesthesia.

Authors:  Zhihua Guo; Wenlong Shao; Weiqiang Yin; Hanzhang Chen; Xin Zhang; Qinglong Dong; Lixia Liang; Wei Wang; Guilin Peng; Jianxing He
Journal:  J Thorac Dis       Date:  2014-01       Impact factor: 2.895

3.  Strategy of intentional limited resection for lung adenocarcinoma in situ.

Authors:  Terumoto Koike; Teruaki Koike; Masaya Nakamura; Yuki Shimizu; Tatsuya Goto; Seijiro Sato; Masanori Tsuchida
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  Lobectomy and limited resection in small-sized peripheral non-small cell lung cancer.

Authors:  Terumoto Koike; Teruaki Koike; Seijiro Sato; Takehisa Hashimoto; Tadashi Aoki; Katsuo Yoshiya; Yasushi Yamato; Takehiro Watanabe; Kohei Akazawa; Shin-Ichi Toyabe; Masanori Tsuchida
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 5.  The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management.

Authors:  Yong Tang; Zhe He; Qihang Zhu; Guibin Qiao
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 6.  Reclassification of early stage pulmonary adenocarcinoma and its consequences.

Authors:  Annikka Weissferdt; Cesar A Moran
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 7.  Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Authors:  Swaroop Revannasiddaiah; Priyanka Thakur; Bhaskar Bhardwaj; Sridhar Papaiah Susheela; Irappa Madabhavi
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 8.  Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.

Authors:  Ming-Ching Lee; Kyuichi Kadota; Daniel Buitrago; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 9.  Emerging treatment options in the management of non-small cell lung cancer.

Authors:  Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini
Journal:  Lung Cancer (Auckl)       Date:  2011-06-08

10.  Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.

Authors:  Aritoshi Hattori; Kenji Suzuki; Takeshi Matsunaga; Mariko Fukui; Yukio Tsushima; Kazuya Takamochi; Shiaki Oh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.